SUPN

#1826
Supernus Pharmaceuticals, Inc. - Common Stock
44.0 7 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
43.67
44.13
Jahresspanne
42.45
59.68
Tagesänderung
+0.75%
Monatliche Änderung
-12.65%
6 month change
-18.79%
Jahresänderung
-18.39%
Vorheriger Schlusskurs
43.7 4
Open
44.0 1
Tief
43.6 7
Hoch
44.1 3
Volumen
387
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 24 April 2013

Full document

Business Context and Reporting Period

This Form 8-K Current Report from Supernus Pharmaceuticals, Inc. covers events occurring on April 24, 2013. The filing primarily details the results of the Company's Annual Meeting of Stockholders and announces a planned capital raise through the issuance of Convertible Senior Secured Notes.

Key Financial Metrics

The filing does not provide specific revenue, profit, cash flow, margin, or liquidity figures. The only quantitative financial data disclosed relates to a proposed debt offering:

  • Proposed Convertible Notes: $75.0 million aggregate principal amount due 2019.
  • Over-Allotment Option: Up to an additional $15.0 million.
  • Outstanding Shares (as of March 20, 2013): 30,892,070 shares of common stock.

Material Changes and Corporate Actions

Annual Meeting Results

Stockholders voted on two proposals at the Annual Meeting held on April 24, 2013:

  • Proposal 1 (Election of Class I Directors): All three nominees were elected.
    • Jack A. Khattar: 22,230,389 votes for; 26,198 withheld.
    • M. James Barrett, Ph.D.: 21,767,284 votes for; 489,303 withheld.
    • William A. Nuerge: 22,226,027 votes for; 30,560 withheld.
  • Proposal 2 (Ratification of Auditors): The appointment of Ernst & Young LLP was ratified.
    • Votes For: 28,973,901
    • Votes Against: 6,675
    • Abstain: 65,004

Capital Markets Activity

The Company announced its intent to offer $75.0 million in Convertible Senior Secured Notes to qualified institutional buyers under Rule 144A. This transaction is subject to market conditions and other considerations.

Guidance, Outlook, and Risks

The filing does not contain updated financial guidance, management commentary on operational outlook, or specific risk factors beyond the standard disclosure that the note offering is subject to market conditions. The press release regarding the notes is incorporated by reference as Exhibit 99.1.

Investor Verification Checklist

  • Verify the final terms and pricing of the $75.0 million Convertible Senior Secured Notes offering.
  • Confirm whether the 30-day option to purchase an additional $15.0 million in notes was exercised.
  • Review the full text of the press release (Exhibit 99.1) for details on the use of proceeds and note covenants.
  • Check subsequent filings for the official closing of the debt transaction.

Nachrichten